Rubicon Research Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ctarxto1nn9gsk96e6iu78ti.pdf

Key Takeaways


Revenue Growth & Commercial Engine

Parag Sancheti: "Last quarter, if you remember, we discussed that we have taken certain tactical measures that led to a pause in our sequential USD revenue growth. We had guided that the growth will be back in Q2. In that light, I am very happy to share that this quarter, our sequential USD revenue growth is 5%, and we continue to see strong visibility in the coming quarters."

Margins & Cash Flow

Parag Sancheti: "If you remember, we last quarter said it will be about 23% plus, which is over our 22%, 23% said earlier. We are happy to report that now we are guiding it to 24% plus for the full year. Just wanted to emphasize, despite difficult geopolitical situations, we still have been able to deliver very strong EBITDA growth."

R&D Engine & Productivity

Sagar Oak: "In many ways, I think we are now building up steam for that uptick that we have pointed out here. Based on this, I think we have tried to represent this a little bit differently just to bring out the various aspects of this. I hope it's easy to appreciate the visibility on revenue growth for 2029, 2030, and beyond is pretty strong for us."

Pre-Revenue Assets & Capital Deployment

Parag Sancheti: "Just to add, Harsh, I think first, I think we, instead of guiding, we believe in doing and not talking. First, again, the focus, as Nitin said, would be on revenue and then on margins. But we still, these are early days for that business."

Regulatory & Compliance

Sagar Oak: "All these observations are procedural. None of them relate to data integrity. This is a very recent inspection. This inspection is literally days old, not even weeks old. We are confident of working with the regulator to close this successfully and in a timely manner."

Guidance & Commitments

CommitmentSpecificsTimeline
Operating EBITDA marginFull-year FY27 at 24% plus (raised from 23% plus)FY27
Sequential USD revenue growthStrong visibility maintainedComing quarters
Working capital normalization125–130 days rangeNormal course
Low-margin product rationalizationA few remaining products to be completedNext 1–2 quarters
Indore (Pithampur) revenue generationRevenue expectedFY28 onwards
Ambernath FDA observationsConfident of successful, timely closure with regulatorNot specified
Incremental R&D spend₹500 crores incremental R&D to drive incremental revenues to FY30 at the productivity rate of that R&DFY27–FY30 cycle
R&D spend guidanceWell on track to achieve ₹500 crores; good visibility on completing remaining spendNext three quarters

Key Metrics

MetricQ2 FY27
Revenue₹577 cr, +40% YoY and +8% QoQ
Pre-R&D EBITDA margin35.8%, +170 bps YoY
Operating EBITDA margin25.0%, up from Q1 FY27; full-year guidance raised to 24%+
PAT₹90 cr, +67% YoY; Q1 FY27 was ₹85 cr including ₹3.6 cr one-time insurance claim
EPS₹5.41, vs ₹3.47 in Q2 FY26
H1 FY27 revenue₹1,111 cr, +45% YoY
H1 FY27 PAT₹175 cr, +80% YoY
Sequential USD revenue growth5%, rebounding after tactical measures paused growth in Q1
R&D spend₹62 cr, 10.8% of revenue, in line with Q2 FY26 and Q1 FY27
Specialty contribution to gross profit36%
ANDA approvals in Q23
Commercialization rate84%
Net working capital days117 days, improved from 126 days as of March 2026; expected to normalize at 125–130 days
ROACE36%, in line with March 2026; ~₹400 cr of capital employed in pre-revenue assets
H1 FY27 net cash flow from operations₹99 cr